Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Or does it?
The four studies linked and excerpted below document four important issues that NDMM patients must wrap their brains around before they begin any toxic therapy.
The only thing that the studies below illustrate is that aggressive, high-dose therapies resulting from an ASCT result in toxicity and short, long-term and late stage side effects.
As I’ve said over and over again, NDMM patients must manage toxicity carefully throughout their survival. The human body can heal from the damage done by toxic chemotherapy but evidence-based, non-toxic, non-conventional nutrition, supplementation and lifestyle therapies must mix with low-dose toxic chemo if the patient is to balance quality with quantity of life.
Regularly being tested in an effort to keep an eye on your incurable blood cancer.
To learn more about evidence-based, non-toxic MM therapies, scroll down the page, post a question or comment and I will reply to you ASAP.
Thanks and hang in there,
“Novel drugs and drug combinations have improved outcomes for multiple myeloma patients. However, subgroups of patients still have a poor progression‐free survival (PFS) and overall survival (OS)…
Conclusion- Our results show that the dramatic improvement in outcome for MM patients during the last 20 years only applies for standard‐risk patients, while high‐risk MM patients still are doing poorly, indicating that the novel drugs developed during this time are preferentially effective in standard‐risk patients.
New treatment modalities like CAR‐T cells, CAR‐NK cells, and/or bispecific antibodies should be tried in clinical studies early in the course of the disease, especially in patients with high‐risk cytogenetics.
“In their study, Shah et al analyzed a prospective observational cohort study of patients with newly diagnosed multiple myeloma (MM) and determined that 40% would have been considered ineligible for most randomized controlled trials (RCTs) based on standard eligibility criteria.
These patients had a lower 3-year overall survival rate compared to the RCT-eligible patients (63% vs. 70%). This study raised important observations regarding the external validity of RCTs in the myeloma population…”
“Between January 1994 and December 2010, 406 consecutive newly diagnosed MM patients received first line therapy in the Department of Clinical Therapeutics (Athens, Greece).
All patients had symptomatic disease, based on the IMWG criteria of that period (at least one CRAB symptom to start anti-myeloma therapy). Thirty-six (8.8%; 23M/13F) patients achieved a PFS of at least 7 years (long PFS group) after frontline treatment.
The median PFS of these 36 patients is 10 years, while the other patients had a median PFS of 22 months…
In conclusion, our study in an unselected group of patients, the majority of whom did not participate in clinical trials, showed that 9% of patients with newly diagnosed myeloma experience prolonged PFS of more than 7 years (median: 10 years) even in the era of CC or first-generation novel agents.
These patients have:
“However, hematopoietic stem cell transplantation (HSCT) survivors are at risk of developing long-term complications, such as
These complications have a direct impact on the morbidity and mortality experienced by HSCT survivors. Two-thirds of HSCT survivors develop at least one chronic health condition; while a fifth develop severe or life-threatening conditions. HSCT patients who have survived for at least 5 years post-transplantation are at a fourfold to ninefold increased risk of late mortality for as long as 30 years from HSCT, producing an estimated 30% lower life expectancy compared with the general population…